Malignant Breast Neoplasm — Trials

Malignant Breast Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

12,355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,627
Recruiting: 1,396
Ph III recruiting: 150
Growth YoY: +23%
Industry share: 18%
Top sponsor: Fudan University
Termination share: 25.6%
Trials / 1,000 deaths: 61.5 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,367)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07536815	An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)	available	—	—	CytoDyn, Inc.INDUSTRY	1	Apr 27, 2026	clinicaltrials
NCT04085653	Managed Access Programs for BYL719, Alpelisib	available	—	—	Novartis PharmaceuticalsINDUSTRY	0	Apr 14, 2026